Form 4: ADMA CFO's Routine Stock Withholding for RSU Vesting

ADMA Biologics' CFO, Brad L. Tade, reported a mandatory withholding of 6,479 shares to cover tax obligations upon the vesting of restricted stock units.

Summary

• Brad L. Tade, CFO and Treasurer of ADMA Biologics, Inc. (ADMA), reported a transaction on February 19, 2026.
• The transaction involved the disposition of 6,479 shares of common stock at a price of $16.32 per share.
• This disposition was not an an open market sale but represented shares withheld by the Issuer to satisfy mandatory tax withholding requirements upon the vesting of restricted stock units (RSUs).
• Following this transaction, Brad L. Tade beneficially owns 232,940 shares of common stock.
• The total beneficial ownership includes 46,671 unvested RSUs from a February 19, 2025 grant, 54,300 unvested RSUs from a July 24, 2024 grant, 37,500 unvested RSUs from a February 26, 2024 grant, and 50,000 unvested RSUs from a June 26, 2023 grant, all vesting quarterly over four years.
• Beneficial ownership also includes 44,469 shares acquired through open market purchases and previous RSU vesting after tax withholding.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While shares were 'disposed of,' it was a mandatory tax withholding due to RSU vesting, which is a positive compensation event for the executive and a routine part of executive incentive plans.

Positives

• The underlying event is the vesting of restricted stock units, which represents earned compensation for the CFO, indicating continued executive retention and performance.
• The CFO continues to hold a significant number of shares and unvested RSUs (232,940 shares beneficially owned), aligning his interests with shareholders.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

StockSavvy.ai notes that mandatory tax withholdings upon RSU vesting are a standard practice in executive compensation across various industries, particularly in biotechnology and pharmaceuticals, where long-term incentive plans are common. This transaction is a routine event and does not reflect a discretionary sale by the executive.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction related to executive compensation, not a signal of management's view on the stock's future performance.
• Employees: Reinforces the company's executive compensation structure, which includes long-term equity incentives.

Next Steps

• Future vesting of the remaining unvested Restricted Stock Units (RSUs) on their respective annual anniversary dates over four years, subject to continued service.

Key Dates

Keywords

ADMA Biologics, ADMA, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Tax Withholding, CFO, Executive Compensation